Wednesday, March 25, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Healthcare

ZimVie Shareholders Approve Acquisition, Set for October Delisting

Dieter Jaworski by Dieter Jaworski
October 12, 2025
in Healthcare, Mergers & Acquisitions, Pharma & Biotech
0
ZimVie Stock
0
SHARES
40
VIEWS
Share on FacebookShare on Twitter

ZimVie Inc. is poised to conclude its tenure as a publicly traded entity after shareholders formally approved its acquisition by private equity firm ARCHIMED. The transaction, scheduled for completion on October 20, has now cleared its final significant obstacle.

Investors will receive $19.00 per common share in cash, representing a substantial premium of approximately 99% over the stock’s 90-day average trading price prior to the acquisition announcement. This values the entire company at around $730 million.

Exceptional Returns for Equity Holders

The $19.00 per share purchase price notably exceeds the average analyst price target of $17.75. Market observers had maintained a cautious stance toward the stock, with five analysts most recently issuing “reduce” recommendations. ARCHIMED’s offer, however, delivers an unexpectedly favorable outcome for shareholders.

Following the transaction’s finalization, ZimVie shares will be delisted from the Nasdaq Global Select Market, marking the company’s transition to private ownership.

Should investors sell immediately? Or is it worth buying ZimVie?

Strategic Transformation Culminates in Buyout

This acquisition represents the culmination of an extended strategic repositioning for the company. Earlier this year, in April 2024, ZimVie divested its spine business to H.I.G. Capital for $375 million, subsequently focusing exclusively on its dental implant operations.

Recent corporate activities had signaled the impending takeover. The company withdrew its annual guidance in July and canceled its earnings presentation. Their most recent quarterly report disclosed revenue of $116.7 million and adjusted earnings per share of $0.26.

Final Steps Toward Completion

With shareholder approval secured, only standard closing conditions remain before the October 20 finalization. For investors, this means they will receive their cash consideration within days while bidding farewell to ZimVie as a publicly traded security.

Ad

ZimVie Stock: Buy or Sell?! New ZimVie Analysis from March 25 delivers the answer:

The latest ZimVie figures speak for themselves: Urgent action needed for ZimVie investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 25.

ZimVie: Buy or sell? Read more here...

Tags: ZimVie
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

Analysis

Ocugen Shares Slide Despite Positive Clinical Trial Results

March 25, 2026
ImmunityBio Stock
Analysis

Regulatory Rebuke Sends ImmunityBio Shares Tumbling

March 25, 2026
IBM Stock
Analysis

IBM Shares Face Pressure from Analyst Downgrades and Acquisition Concerns

March 25, 2026
Next Post
Rocket Lab USA Stock

Space Sector Surge Continues as Rocket Lab Gains Momentum

American Tower Stock

American Tower Faces Critical Test Ahead of Quarterly Earnings

MP Materials Stock

Rare Earths Showdown: How China's Export Curbs Fuel MP Materials' Ascent

Recommended

ServiceNow Stock

ServiceNow Accelerates AI Push with Pyramid Analytics Agreement

1 month ago
QuantumScape Stock

QuantumScape Leadership Exodus Sparks Investor Concerns

4 months ago
Fiserv Stock

Fiserv Shares Hit New Low Despite Strategic Acquisition Push

6 months ago
Star Copper Stock

Star Copper Secures Major Funding for Exploration Drive

2 weeks ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

IBM Shares Face Pressure from Analyst Downgrades and Acquisition Concerns

Battalion Oil Navigates Debt and Operational Overhaul

Divergent Analyst Views Highlight Coeur Mining’s Strategic Transition

Rocket Lab Stock Attracts Bullish Analyst Sentiment Amid Growth Trajectory

TSMC’s Arizona Expansion Gains Momentum Amid Record Retail Investor Interest

Salesforce Shares Face Pressure from External AI Innovation

Trending

Analysis

Ocugen Shares Slide Despite Positive Clinical Trial Results

by SiterGedge
March 25, 2026
0

In a counterintuitive market reaction, Ocugen's stock price declined significantly following the announcement of encouraging 12-month data...

ImmunityBio Stock

Regulatory Rebuke Sends ImmunityBio Shares Tumbling

March 25, 2026
Realty Income Stock

Realty Income’s Strategic Financing Defies High Interest Rate Environment

March 25, 2026
IBM Stock

IBM Shares Face Pressure from Analyst Downgrades and Acquisition Concerns

March 25, 2026
Battalion Oil Stock

Battalion Oil Navigates Debt and Operational Overhaul

March 25, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Ocugen Shares Slide Despite Positive Clinical Trial Results
  • Regulatory Rebuke Sends ImmunityBio Shares Tumbling
  • Realty Income’s Strategic Financing Defies High Interest Rate Environment

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com